Eletriptan

Drug Profile

Eletriptan

Alternative Names: Relert; Relpax; UK 116044

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antimigraines; Pyrrolidines; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Menstrual migraine; Migraine

Most Recent Events

  • 11 Apr 2003 Data presented at the 55th Annual Meeting of the American Academy of Neurology (AAN-2003) have been added to the adverse events , pharmacokinetics section , and Nausea and migraine therapeutic trials section
  • 03 Mar 2003 Launched for Migraine in USA (PO)
  • 16 Jan 2003 Launched for Migraine in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top